Archives
Tirbanibulin in HPV-Positive HeLa Cells
2026-08-16
This 2024 study shows that tirbanibulin suppresses proliferation of HPV-18-containing HeLa cells while reducing protein expression across Src–MEK-associated, cell-cycle, invasion, and survival pathways. Its integrated immunoblotting approach provides a mechanistic framework for understanding how an approved actinic keratosis treatment may also affect HPV-associated oncogenic signaling, while leaving direct antiviral and clinical efficacy questions unresolved.
ATM Inhibition and Fenofibrate in HGSOC
2026-08-15
The reference study identifies a metabolic vulnerability associated with ATM activity in high-grade serous ovarian cancer (HGSOC). It shows that pharmacologic ATM inhibition can synergize with fenofibrate, a PPARα agonist, to induce senescence in HGSOC cells, offering a combination strategy that extends beyond conventional DNA damage-based treatment.
AZD0156: Reliable ATM Inhibition in Viability Assays
2026-08-14
Learn how AZD0156 (SKU B7822) can support better-controlled cell viability, proliferation, and cytotoxicity studies by combining selective ATM pathway inhibition with practical formulation guidance. This scenario-driven guide addresses metabolic assay confounding, solvent compatibility, protocol design, interpretation, and product-selection criteria.
Q-VD(OMe)-OPh: Pan-Caspase Inhibition Guide
2026-08-13
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for controlled apoptosis experiments. Its recombinant-caspase activity profile and low reported cytotoxicity make it useful for apoptosis assay design, pathway dissection, and interpretation of complex cell-death models.
Cardamomin Protects Against Oxidative Ischemic Injury
2026-08-12
The reference study links cardamomin from Amomum villosum stems and leaves to protection against hydrogen peroxide-induced oxidative damage and permanent cerebral ischemia. Its central contribution is a multi-level mechanism involving MEK/ERK-driven NRF2 activation, suppression of oxeiptosis and parthanatos, and improved tissue viability in a rat stroke model.
Q-VD(OMe)-OPh: Designing Better Apoptosis Evidence
2026-08-12
A translational guide to using Q-VD(OMe)-OPh as a mechanistic control in complex cell-death studies, with lessons from cetuximab-resistant colorectal cancer research and applications in cancer differentiation and neuroprotection.
WEHI-539: Practical BCL-XL Apoptosis Workflows
2026-08-11
Learn how WEHI-539, SKU A3935, can improve the interpretation and reproducibility of BCL-XL-dependent apoptosis experiments. This scenario-driven guide covers assay design, handling constraints, mechanistic controls, data interpretation, and vendor-selection considerations.
Naftifine HCl: A Cross-Scale Assay Framework
2026-08-11
Naftifine HCl is an allylamine antifungal agent whose sterol-targeting mechanism supports rigorous, multi-readout fungal assays. This article applies the evidence architecture of a landmark WNT5a/GSK3/β-catenin study to improve assay design while clearly separating fungal pharmacology from muscle-cell biology.
Pseudo-UTP: From IVT Chemistry to Translational Assays
2026-08-10
Pseudo-UTP enables mRNA synthesis with pseudouridine modification, but its value extends beyond RNA stability enhancement. This article connects nucleotide selection, LNP delivery, and disease-relevant assay design using insights from a targeted mRNA study in ischemic stroke.
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-08-07
Calpain Inhibitor I, ALLN (SKU A2602) is a DMSO-soluble cysteine-protease inhibitor for workflows examining calpain and cathepsin contributions to apoptosis, inflammation, and ischemia-reperfusion injury. It should be used with vehicle controls and orthogonal readouts, and is not intended for diagnostic, therapeutic, or single-protease-specific applications.
AZD0156 and ATM Inhibition: Precision Tools for DNA Repair R
2026-08-02
Explore the scientific advances and practical implications of using AZD0156, a potent ATM kinase inhibitor, for dissecting DNA double-strand break repair and checkpoint modulation. This article delivers a unique, evidence-driven perspective on integrating ATM inhibition into cancer therapy research and experimental design.
Rucaparib (AG-014699): Revolutionizing DNA Damage Response A
2026-08-01
Rucaparib (AG-014699) opens new horizons in DNA damage response research, offering precise radiosensitization in PTEN-deficient and ETS fusion-positive cancer models. This guide dives deep into advanced protocols, troubleshooting, and the transformative fallout of Pol II degradation findings for experimental design.
Rotenone as a Mitochondrial Complex I Inhibitor: Advanced Wo
2026-07-31
Rotenone is the gold-standard mitochondrial Complex I inhibitor, enabling precise modeling of mitochondrial dysfunction, apoptosis, and autophagy in both cellular and in vivo studies. Discover optimized protocols, troubleshooting strategies, and recent breakthroughs that enhance the reproducibility and translational value of rotenone-based disease models.
KX2-391 Dihydrochloride: Precision Src Inhibition in Melanom
2026-07-30
Explore the dual mechanism of KX2-391 dihydrochloride as a precise Src kinase and tubulin inhibitor in cancer research. This article uniquely dissects its translational value in conjunctival melanoma and antiviral studies, offering advanced protocol insights and actionable comparisons.
Chlamydial OmpA Vesicles Block Mitochondrial Apoptosis in Ho
2026-07-28
This study reveals that Chlamydia trachomatis delivers its outer membrane protein OmpA to host mitochondria via bacterial membrane vesicles, where OmpA directly inhibits apoptotic signaling by interacting with BCL-2 family effectors. These mechanistic findings provide new insight into how intracellular pathogens actively evade host cell death, with broad implications for apoptosis research.